Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 233Lung Neoplasms 96Adenocarcinoma of Lung 39Colorectal Neoplasms 21Adenocarcinoma, Bronchiolo-Alveolar 19Neoplasms 18Small Cell Lung Carcinoma 13Non-Squamous Non-Small Cell Lung Cancer 13Brain Neoplasms 13Neoplasm Metastasis 10Ovarian Neoplasms 9Pleural Effusion, Malignant 8Breast Neoplasms 8Stomach Neoplasms 7Pancreatic Neoplasms 7Meningeal Carcinomatosis 7Mesothelioma 6Melanoma 6Endometrial Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Rectal Neoplasms 4Non-squamous Non-small Cell Lung Cancer 4Carcinoma, Renal Cell 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Non-small Cell Lung Cancer Metastatic 3Mesothelioma, Malignant 3Esophageal Neoplasms 3Colonic Neoplasms 3

Interventions

motexafin gadolinium 1Rhenium 1Poly I-C 1Erlotinib Hydrochloride 1Bevacizumab 1Anesthesia, General 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Recurrence, Local × Bevacizumab × Thoracic × Clear all
NCT00095225 2008-01-29

A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)

Genentech, Inc.

Phase 2 Completed
122 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Recurrence, Local, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡